Optimized antibodies that target HM1.24

US8394374B2 · kind B2 · utility

Assignee

• Xencor, Inc. · US

Inventors

• Matthew Bernett · Monrovia, US
• John Desjarlais · Pasadena, US
• Sher Bahadur Karki · Pasadena, US
• Gregory Alan Lazar · Los Angeles, US
• Umesh Muchhal · Monrovia, US
• Duc-Hanh Thi Nguyen · San Fernando, US
• John O. Richards · Duarte, US

Key dates

• Filing date: Sep 18, 2007
• Grant date: Mar 12, 2013
• Expiry date: Jul 8, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.